semaglutide oral pill for weight loss FDA Sets Action Date Wegovy for The approval of another oral

Contraindications and Use Restrictions GLP-1 medications should not be used by individuals with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, known hypersensitivity to semaglutide, or during pregnancy or breastfeeding

As we continue to innovate and build on our unique model of scientifically-proven medications, personalized nutrition plans, and expertly-curated meals, our advisors will be instrumental in achieving our vision of a future where each person is inspired and empowered to confidently take control of their well-being

Data Availability Statement Data underlying this article are not publicly available to preserve the privacy of patients included

Roche with its 2024 acquisition of Carmot, and Pfizer, following its 2025 acquisition of Metsera, enter obesity and broaden their presence in cardiovascular/metabolic, while other large pharmaceutical companies prepare to follow later in the decade

Those aged 50 to 64 have seen their obesity rate drop 5.0 points to 42.8%, with 17.0% currently reporting use of the medicine

Gupta's medical supervision